Friday 22 February 2019 ,
Friday 22 February 2019 ,
Latest News
  • Chawakbazar fire virtually repeats 2010 Nimtali tragedy
  • UK deeply saddened over Dhaka fire
  • BNP blames govt's irresponsibility for Chawkbazar fire
  • Shamima not a Bangladeshi citizen; no entry for her: Dhaka
  • Provide proper treatment to Chawkbazar fire victims: PM
  • probe body formed over Chawkbazar fire
  • Death toll jumps to 81 in Chawkbazar fire
10 September, 2018 00:00 00 AM / LAST MODIFIED: 10 September, 2018 01:15:26 AM

FDA approves Xerava

drugs.com
FDA approves Xerava

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, recently announced that the U.S. Food and Drug Administration (FDA) has granted approval of Xerava (eravacycline) for the treatment of complicated intra-abdominal infections (cIAI). In clinical trials, Xerava was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem.

Xerava is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

“The approval of Xerava is an extraordinary achievement, one for which we thank the patients who have participated in our clinical studies, study investigators and physicians as well as our dedicated employees,” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We are thrilled to have received FDA approval, and a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in Europe all within the same quarter. Each milestone is a significant accomplishment on its own and achieving both underscores the potential for Tetraphase and the medical need for Xerava.”

Dr. Barie added, “Eravacycline also has a favorable safety profile as observed in clinical trials, and no dose adjustment is required when given to patients with renal impairment, which is advantageous for seriously ill patients who may have impaired kidney function. Additionally, the drug may be given safely to patients who are allergic to penicillin. This new and novel treatment may be of great benefit to patients with complicated intra-abdominal infections.”

Intra-abdominal infection (IAI) is a common problem in clinical practice and comprises a wide variety of disease processes. IAI is classified as uncomplicated or complicated based on the extent of the infection. Complicated intra-abdominal infections (cIAI) extend beyond the source organ into the peritoneal space (the space between the two membranes that separate the organs in the abdominal cavity from the abdominal wall) as a result of perforation or other damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. Different bacterial pathogens are responsible for cIAI, including Gram-negative aerobic bacteria, Gram-positive bacteria, and anaerobic bacteria.

Early detection, containment and appropriate antimicrobial treatment are essential to the successful treatment of IAI. This is even more critical with increasing rates of infections caused by drug-resistant bacteria, which limit the effectiveness of currently available antibiotics.

Important safety information

Xerava is a tetracycline class antibacterial indicated for the treatment of complicated intra abdominal infections in patients 18 years of age and older.

Xerava is not indicated for the treatment of complicated urinary tract infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Xerava and other antibacterial drugs, Xerava should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Xerava is contraindicated for use in patients with known hypersensitivity to eravacycline or to tetracycline-class antibacterial drugs. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with Xerava.

The use of Xerava during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of Xerava during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea, and vomiting.

Xerava is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri, and anti anabolic action which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with Xerava. Discontinue Xerava if any of these adverse reactions are suspected.

About Xerava

Xerava (eravacycline for injection) is a novel, fully-synthetic fluorocycline, FDA-approved antibiotic for the treatment of cIAI. Xerava has demonstrated potent activity against MDR pathogens.

Xerava was investigated for the treatment of cIAI as part of the Company's IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) phase 3 programs. In the first pivotal phase 3 trial in patients with cIAI, twice-daily intravenous (IV) eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second phase 3 clinical trial in patients with cIAI, twice-daily IV eravacycline met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, Xerava achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates.

 

 

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

Our cover story this week is on Dental Disorders. Teeth are a very important part of the human body. They are the body's hardest and most durable…
Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

Cancer’s long-term prognosis: As an oncologist I’ve never been so hopeful

“You’re an oncologist, isn’t that depressing?” Answering this question, posed with equal parts dread and fascination, is an occupational…
What are the most common dental problems?

What are the most common dental problems?

Tammy Davenport    Dental problems are never any fun, but the good news is that most of them can be easily prevented. Brushing twice a day,…
Tooth, cavities and root canal

Tooth, cavities and root canal

Our dental surgeons now a days talk about re-construction of a broken tooth with a chemical compound they call 'miracle mix' or magic mix'…
What can you do about sensitive teeth?

What can you do about sensitive teeth?

If you pass on hot or cold drinks because you know they’ll make your teeth hurt, it may be time to talk to your dentist about the possibility that…
Everything you need to know about bad breath

Everything you need to know about bad breath

Tim Newman Bad breath affects an estimated 25 percent of people. There are a number of possible causes of halitosis, but the vast majority come down to…
7 Daily ways to protect your teeth

7 Daily ways to protect your teeth

Some say the eyes are the window to the soul. But if you really want to know what someone’s about, check their smile. A welcoming show of pearly…
Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation

Researchers at the University of Virginia School of Medicine have identified an unexpected contributor to rheumatoid arthritis that may help explain the…
Enhance social emotional learning along with cognitive capacity of the children with NDDs

Enhance social emotional learning along with cognitive capacity of the children with NDDs

Neurodevelopmental disorders (NDDs) are indicated by developmental deficits which usually appear at the early age of a child’s development and can…
icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b explores sustainable ways to improve WASH and menstrual hygiene management in RMG factories

icddr,b in partnership with The Waterloo Foundation, UK have undertaken a new study to explore water, sanitation and hygiene (collectively known as WASH)…
Researchers find clues that depression may speed brain aging

Researchers find clues that depression may speed brain aging

Memory and thinking skills naturally slow with age but now scientists are peeking inside living brains to tell if depression might worsen that decline—and…
FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

FDA approves Spravato (esketamine) nasal spray for adults with treatment-resistant depression

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic…
FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

FDA approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), first generic of advair diskus

Mylan N.V. recently announced the U.S. Food and Drug Administration (FDA) approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder,…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting